Drugdocs | Bimzelx®

Drug updated on 4/16/2024

Dosage Form	Injection (subcutaneous; 160 mg/mL in a single-dose prefilled syringe or single-dose prefilled autoinjector)
Drug Class	Humanized interleukin-17A and F antagonists
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

Indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Bimekizumab (Bimzelx) demonstrates a highly favorable profile for efficacy across multiple clinical endpoints in both psoriatic arthritis and plaque psoriasis, showing superior performance in achieving minimal disease activity, PASI 90, and PASI 100 across various subgroups.
Eight studies were reviewed to derive insights about the drug's safety, efficacy, and comparisons with other treatments for moderate-to-severe plaque psoriasis.
Compared to other biologics used for similar conditions, Bimzelx ranks highly in terms of joint outcomes and skin results. It outperforms or is comparable to most other biological/targeted synthetic DMARDs.
The safety profile of Bimzelx is reported as being on par with that of other biologics. Oral candidiasis emerges as one common treatment-emergent adverse event specific to this drug, but overall its adverse event profile does not significantly diverge from that of others.
Subgroup analyses within the studies stress that Bimzelx's efficacy remains consistent across different dosing intervals after initial maintenance without significant differences; it also shows rapid onset action regardless of previous treatment exposures, underscoring a potential advantage among patient populations.
Despite a relatively higher incidence rate compared to some IL inhibitors, there was no noted impact on effectiveness due to anti-drug antibodies development in patients treated with Bimzelx.

Document Title	Year	Source
Bimzelx (bimekizumab) Prescribing Information.	2023	UCB Inc., Smyrna, GA

Document Title	Year	Source
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: A systematic literature review and network meta-analysis.	2024	Rheumatology
Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials.	2023	Therapeutic Advances in Chronic Disease
Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials.	2023	Journal of Dermatological Treatment
Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and network meta-analysis of randomized clinical trials.	2023	Journal of the American Academy of Dermatology.
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.	2023	The Cochrane database of systematic reviews
Meta-analysis and GRADE assessment of randomized controlled trials on the efficacy and safety of bimekizumab in psoriatic arthritis patients.	2023	Therapeutic Advances in Chronic Disease
Anti-drug antibodies of IL-17 inhibitors for psoriasis: a systematic review.	2022	The Journal of dermatological treatment
Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis.	2022	Dermatology and Therapy
Long-term benefit–risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis.	2022	Dermatology and Therapy

Document Title	Year	Source
English version of Japanese guidance for use of biologics for psoriasis (the 2022 version).	2022	The Journal of Dermatology